Ascendia

  MARKET NEWS

Nasus Pharma Announces Initiation of Phase 2 Clinical Study of NS002 with First Participant Dosed
Agomab Announces Positive Topline Phase 2a Data for Ontunisertib in Fibrostenosing Crohn’s Disease 
One-carbon Therapeutics AB Announces First Subject Dosed in the ODIN Phase 1/2 Clinical Study of TH9619 in Advanced Solid Tumors
Acumen Pharmaceuticals Announces First Participant Dosed in Phase 2 Open-Label Extension Study of Sabirnetug in People With Early Alzheimer’s Disease
LifeMD to Offer Market-Leading Pricing for GLP-1 Medications Wegovy & Ozempic in Continued Collaboration With Novo Nordisk
Halda Therapeutics Announces Acquisition by Johnson & Johnson
Azurity Pharmaceuticals & Sebela Pharmaceuticals Announce the Sale of Sebela’s Bowel Prep Franchise to Azurity
AEON Biopharma Reports Positive & Robust Biosimilarity Results: Identical Amino Acid Sequence & Highly Similar Functional Analysis Data
Moleculin Reports 60% of First 45 Subjects in Pivotal “MIRACLE” Phase 3 AML Trial Consented
Novartis Opens New Radioligand Therapy Manufacturing Facility as Part of $23B US Expansion Plan

  EXPERT CONTENT & RESOURCES

EXECUTIVE INTERVIEW - Incannex Healthcare: Pioneering the Future of Cannabinoid and Psychedelic Therapies

EXECUTIVE INTERVIEW - Incannex Healthcare: Pioneering the Future of Cannabinoid and Psychedelic Therapies

In this exclusive interview, Latham shares how the company navigates complex global regulatory pathways, building strategic collaborations, and forging a path toward commercial success that balances both scientific rigor and therapeutic optimism.

From Concept to Optimization: A Step-by-Step Guide to SEDDS for Enhanced Oral Bioavailability

From Concept to Optimization: A Step-by-Step Guide to SEDDS for Enhanced Oral Bioavailability

Join Dr. Masumi Dave, Application Lab Manager at Gattefossé USA, for a practical, step-by-step guide to developing optimized Self-Emulsifying Drug Delivery Systems (SEDDS). This webinar provides a proven framework you can apply in your lab to overcome solubility and permeability challenges with lipid excipients.

How Can a Stage-Based Program to Determine HME Applicability Benefit Your API?

How Can a Stage-Based Program to Determine HME Applicability Benefit Your API?

Low bioavailability due to poor API solubility is one of the major challenges to be overcome when developing oral dosage form drug products. An effective way of addressing this problem is to transform low solubility APIs into amorphous solid dispersions (ASDs) and can often be achieved via hot melt extrusion (HME).

  FEATURED EDITORIAL

  COMPANY PROFILE

Upperton is a UK-based CDMO providing integrated contract development and manufacturing services. Specialising in oral, nasal, pulmonary and sterile dosage forms, Upperton offers a comprehensive range of services designed to support the progression of a molecule from early feasibility through to formulation development, clinical trial manufacture and commercial manufacture. Click here for more.

  WHITEPAPERS & WEBINARS

ON-DEMAND WEBINAR: Drug Product Design for Delivery of Challenging Molecules

ON-DEMAND WEBINAR: Drug Product Design for Delivery of Challenging Molecules

In this talk we illustrate several case studies demonstrating how a fundamental understanding of molecular properties combined with a strategic vision for drug product design can lead to effective and advanceable formulations for even the most challenging drug products.

vytal webinar

WEBINAR - Vytal: The RTU Snap-Fit System for Container Closure Solutions – Setting the Standard for the Future

In recent decades, the landscape of parenteral drug production has undergone significant transformation, driven by the emergence of novel molecules and advanced therapies. The pharmaceutical industry has witnessed a notable shift towards biologics, mAbs, and cell-based therapies, which now represent some of the most successful pharmaceutical products globally.

  WHITEPAPERS & WEBINARS

WHITEPAPER - Advancements in Intradermal Delivery: From Historic Techniques to Modern Innovations

WHITEPAPER - Advancements in Intradermal Delivery: From Historic Techniques to Modern Innovations

Abstract

Intradermal delivery has long been a critical method in medical and pharmaceutical fields, offering unique advantages for diagnosis, vaccination and therapeutic applications. This white paper explores the evolution of intradermal delivery methods, comparing historic methods of delivery such as …

WHITEPAPER - An Insoluble Problem? Overcoming Oral Drug Solubility Challenges With Functional Polymers

WHITEPAPER - An Insoluble Problem? Overcoming Oral Drug Solubility Challenges With Functional Polymers

 

The biopharmaceutical classification system classifies drugs according to their permeability and solubility. Drugs with poor solubility and/or permeability are class II or IV type drugs, and these require special formulation technologies for solubility enhancement. In the past 25 …

WHITEPAPER - 3D Reconstructed Skin Models: Transforming Clinical & Safety Testing

WHITEPAPER - 3D Reconstructed Skin Models: Transforming Clinical & Safety Testing

SGS, the world’s leading testing, inspection and certification company, recently announced the release of a new white paper, 3D Reconstructed Skin Models: Transforming Clinical & Safety Testing.

Targeted at researchers, toxicologists and formulation scientists in the clinical and dermatological …

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

November 26 – Bioavailability
December 3 – Inhalation Delivery